These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33868760)

  • 21. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the microbiome, probiotics, and 'dysbiosis therapy' in critical illness.
    Wischmeyer PE; McDonald D; Knight R
    Curr Opin Crit Care; 2016 Aug; 22(4):347-53. PubMed ID: 27327243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Dysbiosis for the Treatment of Liver Disease.
    Anand G; Zarrinpar A; Loomba R
    Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gut Microbiota and Host Reaction in Liver Diseases.
    Fukui H
    Microorganisms; 2015 Oct; 3(4):759-91. PubMed ID: 27682116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The gut microbiota as a novel regulator of cardiovascular function and disease.
    Battson ML; Lee DM; Weir TL; Gentile CL
    J Nutr Biochem; 2018 Jun; 56():1-15. PubMed ID: 29427903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
    Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
    Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbiome as a therapeutic target in alcohol-related liver disease.
    Sarin SK; Pande A; Schnabl B
    J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut microbiome in primary sclerosing cholangitis: A review.
    Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
    World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alcohol, liver disease and the gut microbiota.
    Bajaj JS
    Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota.
    Engen PA; Green SJ; Voigt RM; Forsyth CB; Keshavarzian A
    Alcohol Res; 2015; 37(2):223-36. PubMed ID: 26695747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alcoholic Liver Disease: Update on the Role of Dietary Fat.
    Kirpich IA; Miller ME; Cave MC; Joshi-Barve S; McClain CJ
    Biomolecules; 2016 Jan; 6(1):1. PubMed ID: 26751488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.
    Hartmann P; Hochrath K; Horvath A; Chen P; Seebauer CT; Llorente C; Wang L; Alnouti Y; Fouts DE; Stärkel P; Loomba R; Coulter S; Liddle C; Yu RT; Ling L; Rossi SJ; DePaoli AM; Downes M; Evans RM; Brenner DA; Schnabl B
    Hepatology; 2018 Jun; 67(6):2150-2166. PubMed ID: 29159825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies.
    Zhou R; Fan X; Schnabl B
    Transl Res; 2019 Jul; 209():22-38. PubMed ID: 30853445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The gut microbiome.
    Sidhu M; van der Poorten D
    Aust Fam Physician; 2017; 46(4):206-211. PubMed ID: 28376573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut Microbiota at the Intersection of Alcohol, Brain, and the Liver.
    Gupta H; Suk KT; Kim DJ
    J Clin Med; 2021 Feb; 10(3):. PubMed ID: 33540624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.